000			01427 a2200373 4500
005			20250512004322.0
264		0	_c19890522
008			198905s 0 0 eng d
022			_a0022-1767
040			_aNLM _beng _cNLM
100	1		_aReiter, Y
245	0	0	_aTargeting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. _h[electronic resource]
260			_bJournal of immunology (Baltimore, Md. : 1950) _cApr 1989
300			_a2771-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aComplement C3-C5 Convertases _xpharmacology
650	0	4	_aComplement C3b _xadministration & dosage
650	0	4	_aComplement C3b Inactivator Proteins _xmetabolism
650	0	4	_aComplement Factor H
650	0	4	_aComplement Pathway, Alternative
650	0	4	_aCytotoxicity, Immunologic
650	0	4	_aElapid Venoms _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aImmunotherapy
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Inbred C57BL
650	0	4	_aNeoplasms _ximmunology
650	0	4	_aTumor Cells, Cultured
700	1		_aFishelson, Z
773	0		_tJournal of immunology (Baltimore, Md. : 1950) _gvol. 142 _gno. 8 _gp. 2771-7
999			_c2528938 _d2528938